Moreover, we further demonstrated that IGFBP3 is an important downstream target gene of B-Myb, and that B-Myb activates extracellular signal-regulated kinases (ERK) and Akt signaling at least partially through inhibiting IGFBP3 in NSCLC cells. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.